A Phase 3 interventional study of clarithromycin extended-release tablets and clarithromycin immediate-release tablets in Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)., sponsored by Abbott. Completed at 146 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2008-03-27.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies in Bronchitis, Chronic with a site in United States — 7 open to participants now, 12 under way, none of them phase 3. Bronchitis, Chronic · United States.
Among the 100 studies in Bronchitis, Chronic with a site in United States, this one is the 21st largest by enrollment of the 82 interventional ones that give a count, is one of 5 that started in 2002, is one of 19 in phase 3, and was the 30th registered.
209 studies on the registry are indexed under Bronchitis, Chronic; 14 are open to participants now.
Browse Bronchitis, Chronic studies →7 of the 100 studies in Bronchitis, Chronic with a site in United States are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Austria and 15 more countries
Ages 40–75
UCB Biopharma SRL · Sites in United States, China
Ages 40–80
Rush University Medical Center · Sites in United States
Ages 40+
Freenome Holdings Inc. · Sites in United States
Ages 50+
COPD Foundation · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Bronchitis, Chronic studies recruiting now, 5 (50%) set no upper age limit and 2 (20%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 25 · Phase 3 19 · Phase 4 15
First in 1994; this study’s year is marked. 5 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 465 is above the median of 101 across 154 interventional studies indexed under Bronchitis, Chronic.
Median enrollment 126 across the 82 interventional studies, 1,429 across the 18 observational. Of the 78 that completed or were terminated, 33 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 100 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
Abbott has 3 studies filed under Bronchitis, Chronic — fewer than ten, so there is no comparison to draw.
1 of the studies in Bronchitis, Chronic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06981078Upstream Bio Inc.A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 100 studies in Bronchitis, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare the efficacy of a 5-day course of clarithromycin extended-release tablets (2 x 500 mg QD) with that of a 7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID) in the treatment of acute bacterial exacerbation of chronic bronchitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: clarithromycin extended-release tablets
Drug: clarithromycin immediate-release tablets
5-day course of clarithromycin extended-release tablets (2 x 500 mg QD)
Also known as: ABT-268, Biaxin, clarithromycin
7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)
Also known as: ABT-268, Biaxin, clarithromycin
Clinical Response
Time frame: 23 days
Bacteriologic Response
Time frame: 23 days
Adverse events assessment
Time frame: 42 days with follow-up to a satisfactory conclusion
Physical exam; Vital signs; Use of other medications and supplements
Time frame: 42 days
Laboratory evaluations
Time frame: 23 days
Showing the first 100 of 146 sites across 3 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2002 and a primary completion of Apr 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clarithromycin